×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:LLY

Eli Lilly and Stock Forecast, Price & News

$324.71
+0.48 (+0.15%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$317.76
$325.40
50-Day Range
$282.83
$327.27
52-Week Range
$220.20
$330.85
Volume
1.82 million shs
Average Volume
3.01 million shs
Market Capitalization
$308.53 billion
P/E Ratio
48.11
Dividend Yield
1.21%
Price Target
$311.65

Eli Lilly and Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
4.0% Downside
$311.65 Price Target
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.21mentions of Eli Lilly and in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$355.89 M Sold Last Quarter
Proj. Earnings Growth
14.75%
From $8.27 to $9.49 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Medical Sector

79th out of 1,429 stocks

Pharmaceutical Preparations Industry

28th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

Eli Lilly and logo

About Eli Lilly and (NYSE:LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
53245710
Employees
35,000
Year Founded
1876

Company Calendar

Last Earnings
4/28/2022
Ex-Dividend for 6/10 Dividend
5/13/2022
Dividend Payable
6/10/2022
Today
7/02/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$311.65
High Stock Price Forecast
$369.00
Low Stock Price Forecast
$264.00
Forecasted Upside/Downside
-4.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82352941176471
Research Coverage
17 Analysts

Profitability

Net Income
$5.58 billion
Pretax Margin
22.96%

Debt

Sales & Book Value

Annual Sales
$28.32 billion
Cash Flow
$9.37 per share
Book Value
$9.57 per share

Miscellaneous

Free Float
949,020,000
Market Cap
$308.53 billion
Optionable
Optionable
Beta
0.40

Social Links















Eli Lilly and Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and
or view top-rated stocks.

What is Eli Lilly and's stock price forecast for 2022?

17 Wall Street research analysts have issued 1-year target prices for Eli Lilly and's stock. Their LLY stock forecasts range from $264.00 to $369.00. On average, they anticipate Eli Lilly and's stock price to reach $311.65 in the next twelve months. This suggests that the stock has a possible downside of 4.0%.
View analysts' price targets for Eli Lilly and
or view top-rated stocks among Wall Street analysts.

How has Eli Lilly and's stock performed in 2022?

Eli Lilly and's stock was trading at $276.22 at the beginning of the year. Since then, LLY stock has increased by 17.6% and is now trading at $324.71.
View the best growth stocks for 2022 here
.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Eli Lilly and
.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Thursday, April, 28th. The company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion for the quarter, compared to analysts' expectations of $7.29 billion. Eli Lilly and had a trailing twelve-month return on equity of 97.58% and a net margin of 20.90%. The firm's revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.87 EPS.
View Eli Lilly and's earnings history
.

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, June 27th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.98 per share on Friday, September 9th. This represents a $3.92 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Friday, August 12th.
View Eli Lilly and's dividend history
.

Is Eli Lilly and a good dividend stock?

Eli Lilly and(NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.21%. Eli Lilly and has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Eli Lilly and is 58.07%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 41.31% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

How will Eli Lilly and's stock buyback program work?

Eli Lilly and announced that its Board of Directors has initiated a stock buyback program on Monday, May 3rd 2021, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $8.15-$8.30 for the period, compared to the consensus earnings per share estimate of $8.19. The company issued revenue guidance of $28.80 billion-$29.30 billion, compared to the consensus revenue estimate of $26.80 billion.

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the following people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 54, Pay $4.1M) (LinkedIn Profile)
  • Ms. Anat Ashkenazi, Sr. VP & CFO (Age 49, Pay $1.91M)
  • Dr. Daniel M. Skovronsky M.D., Ph.D., Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs (Age 48, Pay $2.16M) (LinkedIn Profile)
  • Mr. Diogo Rau, Sr. VP & Chief Information and Digital Officer
  • Mr. Jacob S. Van Naarden, Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology (Age 37, Pay $2.01M)
  • Mr. Donald A. Zakrowski, Chief Accounting Officer & VP of Fin. (LinkedIn Profile)
  • Mr. Martin Bott MIBS, VP of Fin. & Special Projects (Age 59)
  • Kevin Hern, VP of Investor Relations
  • Ms. Anat Hakim J.D., Sr. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Alonzo Weems, Sr. VP and Chief Ethics & Compliance Officer

What is David A. Ricks' approval rating as Eli Lilly and's CEO?

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

What other stocks do shareholders of Eli Lilly and own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a variety of institutional and retail investors. Top institutional investors include Park National Corp OH (0.00%) and First Financial Bank Trust Division (0.00%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and
.

Which major investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and First Financial Bank Trust Division. Company insiders that have sold Eli Lilly and company stock in the last two years include Alfonso G Zulueta, Donald A Zakrowski, Ilya Yuffa, Lilly Endowment Inc, and Melissa S Barnes.
View insider buying and selling activity for Eli Lilly and
or view top insider-selling stocks.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $324.71.

How much money does Eli Lilly and make?

Eli Lilly and (NYSE:LLY) has a market capitalization of $308.53 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.75 on an earnings per share basis.

How many employees does Eli Lilly and have?

Eli Lilly and employs 35,000 workers across the globe.

Does Eli Lilly and have any subsidiaries?

The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO BioSciences Inc, ARMO Bioscience, Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma, Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Dermira, Devices for Vascular Intervention(DVI), Disarm Therapeutics, Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services Inc, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly de Centro America S.A., Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc, Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, Kinsale Financial Services Unlimited Company, Lilly (Shanghai) Management Co. Ltd, Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly China Research and Development Co. Ltd., Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Lylly Centre for Clinical Pharmacology PTE. LTD., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Pharmaserve-Lilly S.A.C.I., Physio-Control, SGX Pharmaceuticals, SGX Pharmaceuticals Inc, Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More

When was Eli Lilly and founded?

Eli Lilly and was founded in 1876.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for Eli Lilly and is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.